You just read:

RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period

News provided by

RXi Pharmaceuticals Corporation

Dec 04, 2013, 08:05 ET